• P2Y11 Antagonist NF 340: Precision Tools for Cancer Signalin

  2026-07-27

  NF 340 is a highly selective P2Y11 antagonist enabling researchers to dissect purinergic signaling in cancer and immunology models. This guide details experimental workflows, advanced applications, and troubleshooting strategies to maximize reproducibility and data quality using APExBIO’s NF 340.

• Masitinib (AB1010): Technical Guidance for KIT/PDGFR Assays

  2026-07-26

  Masitinib (AB1010) is a phenylaminothiazole-type tyrosine kinase inhibitor designed for selective inhibition of KIT, PDGFRα, and PDGFRβ in cancer, mastocytosis, and inflammatory disease research. It is best used in DMSO-based protocols targeting the KIT signaling pathway, with well-defined solubility and storage requirements. This compound is unsuitable for workflows requiring aqueous or ethanol solubility, or broad-spectrum kinase inhibition.

• Tolazoline in Integrated Islet-Airway Research: Mechanisms &

  2026-07-25

  Explore Tolazoline as an α2-adrenergic receptor antagonist in depth—unifying mechanisms in insulin secretion and airway smooth muscle studies with advanced, evidence-driven protocol guidance. This article uniquely synthesizes recent findings for translational pharmacology.

• Metal-Ion-Chelating l-Phe Nanostructures Enhance ICB Respons

  2026-07-24

  This study introduces metal-ion-chelating l-phenylalanine nanostructures as a novel tool for reversing immune dysfunction in breast tumors, thereby enhancing the efficacy of immune checkpoint blockade (ICB) immunotherapy. By modulating dendritic cell ion channel activity, these nanostructures remodel the tumor microenvironment, suggesting new strategies to overcome immunosuppression in solid tumors.

• Dimethoxy-Tolazoline Derivatives: Selectivity at α1/α2-Adren

  2026-07-24

  This study systematically evaluates the pharmacology of dimethoxy-substituted tolazoline derivatives, revealing how specific aromatic substitutions confer selective agonist or antagonist activity at α1- and α2-adrenoreceptors. Its findings inform the rational design and application of imidazoline compounds for in vitro receptor signaling and functional studies.

• Afatinib (BIBW 2992): Irreversible ErbB Inhibitor for Cancer

  2026-07-23

  Afatinib (BIBW 2992) is an irreversible tyrosine kinase inhibitor that targets EGFR, HER2, and HER4 with high specificity. This compound is widely used in cancer biology research to dissect resistance mechanisms and optimize targeted therapy strategies. Its robust inhibition profile and solubility properties make it a preferred tool for advanced tumor modeling.

• Mitoxantrone HCl Disrupts ERα via DBD-LBD Interface Targetin

  2026-07-23

  Wang et al. reveal a novel mechanism by which Mitoxantrone HCl targets the allosteric interface between the DNA-binding and ligand-binding domains of estrogen receptor alpha, promoting receptor degradation and disrupting signaling even in therapy-resistant mutants. These findings offer a new paradigm for targeting nuclear receptors beyond classical ligand competition and inform future breast cancer research strategies.

• Mac-1 Deficiency Reduces Cardiac Remodeling via Macrophage M

  2026-07-22

  This study reveals that Mac-1 deficiency significantly ameliorates cardiac dysfunction and remodeling induced by pressure overload, primarily by inhibiting macrophage polarization and activation. The findings provide new mechanistic insight into heart failure progression and highlight Mac-1 as a potential therapeutic target.

• Phenothiazines Boost Macrophage Antibacterial Activity via R

  2026-07-22

  The referenced study demonstrates that phenothiazines significantly enhance macrophage-mediated antibacterial defenses through the induction of autophagy and reactive oxygen species (ROS) accumulation. These findings highlight a promising host-directed therapeutic approach for combating intracellular bacterial infections and antibiotic resistance.

• Catalpol (N1352): Protocol Guidance for Disease Model Resear

  2026-07-21

  Catalpol is a multi-target iridoid glycoside optimized for use in animal and cell-based models relevant to neuroprotection, osteoporosis, ischemic stroke, and liver fibrosis studies. This technical guide outlines practical dosing, solubility, and workflow recommendations for maximizing reproducibility. Use of Catalpol is best avoided in protocols where its pathway selectivity, solubility, or solution stability are not aligned with experimental requirements.

• 25-Hydroxycholesterol-AMPK Axis Shapes Tumor Macrophage Immu

  2026-07-21

  Xiao et al. uncover how 25-hydroxycholesterol (25HC) regulates immunosuppressive tumor-associated macrophages (TAMs) via a lysosomal AMPK activation pathway, influencing STAT6 signaling and tumor immune evasion. These insights highlight CH25H-25HC-AMPK as a pivotal immunometabolic checkpoint with therapeutic implications for cancer immunotherapy.

• DeferoxamineB: Enhancing Cancer Research via Iron Chelation

  2026-07-20

  Deferoxamine (DeferoxamineB) empowers oncology labs to precisely modulate iron-driven cell death, enabling next-generation cancer models and metabolic interventions. This guide delivers advanced protocols, troubleshooting insights, and actionable advantages for integrating DeferoxamineB into ferroptosis and cuproptosis research.

• C34 TLR4 Inhibitor: Precision Modulation of Gut and Immune I

  2026-07-20

  Explore how the C34 TLR4 inhibitor enables selective, high-fidelity modulation of inflammatory pathways in macrophages and enterocytes. This article goes beyond neuroinflammation, providing advanced insights for translational research in gut and systemic inflammatory diseases.

• Medroxyprogesterone Acetate (MPA): Reliable Solutions for La

  2026-07-19

  This article addresses practical challenges in cell viability, proliferation, and reproductive model assays, illustrating how Medroxyprogesterone acetate (SKU B1510) delivers reproducibility and robust mechanistic data. Scenario-based guidance helps biomedical researchers optimize experimental design, interpretation, and product selection using validated protocols and literature-backed insights.

• ML365 Attenuates POCD via NLRP3 Inflammasome Inhibition in M

  2026-07-18

  A recent study demonstrates that the selective TASK1 potassium channel inhibitor ML365 mitigates postoperative cognitive dysfunction (POCD) in aged mice by suppressing NLRP3 inflammasome activation in the hippocampus. This mechanistic insight connects ion channel pharmacology to neuroinflammation, informing neurophysiology research on age-related cognitive impairment.

466 records 11/32 page Previous Next First page 上5页 1112131415 下5页 Last page